| SC 13D/A | 2018-03-15 | Broadfin Capital, LLC | Recro Pharma, Inc. | 2,236,025 | 11.7% | EDGAR |
| SC 13G/A | 2018-03-08 | BlackRock Inc. | Recro Pharma, Inc. | 955,424 | 5.0% | EDGAR |
| SC 13G/A | 2018-02-14 | LYTTON LAURENCE W | Recro Pharma, Inc. | 877,981 | 4.6% | EDGAR |
| SC 13G/A | 2018-02-14 | Flynn James E | Recro Pharma, Inc. | 1,901,685 | 9.9% | EDGAR |
| SC 13G | 2018-02-14 | Alyeska Investment Group, L.P. | Recro Pharma, Inc. | 1,007,853 | 5.3% | EDGAR |
| SC 13G/A | 2018-02-13 | Stonepine Capital Management, LLC | Recro Pharma, Inc. | 1,050,115 | 5.5% | EDGAR |
| SC 13G | 2018-02-01 | BlackRock Inc. | Recro Pharma, Inc. | 1,011,855 | 5.3% | EDGAR |
| SC 13D/A | 2017-12-14 | Broadfin Capital, LLC | Recro Pharma, Inc. | 2,512,025 | 13.1% | EDGAR |
| SC 13D/A | 2017-12-04 | Broadfin Capital, LLC | Recro Pharma, Inc. | 2,705,262 | 14.2% | EDGAR |
| SC 13D/A | 2017-11-24 | Broadfin Capital, LLC | Recro Pharma, Inc. | 2,927,878 | 15.3% | EDGAR |
| SC 13G | 2017-05-19 | LYTTON LAURENCE W | Recro Pharma, Inc. | 1,177,908 | 6.2% | EDGAR |
| SC 13G/A | 2017-05-16 | Stonepine Capital Management, LLC | Recro Pharma, Inc. | 1,902,380 | 10.0% | EDGAR |
| SC 13G/A | 2017-02-14 | Cormorant Asset Management, LLC | Recro Pharma, Inc. | 501,878 | - | EDGAR |
| SC 13G/A | 2017-02-14 | Tourbillon Capital Partners, L.P. | Recro Pharma, Inc. | 646,552 | 3.4% | EDGAR |
| SC 13G/A | 2017-02-14 | Flynn James E | Recro Pharma, Inc. | 2,075,000 | 10.9% | EDGAR |
| SC 13G/A | 2016-12-19 | Stonepine Capital Management, LLC | Recro Pharma, Inc. | 2,874,317 | 15.2% | EDGAR |
| SC 13G | 2016-12-16 | Flynn James E | Recro Pharma, Inc. | 2,075,000 | 10.9% | EDGAR |
| SC 13D/A | 2016-12-14 | Broadfin Capital, LLC | Recro Pharma, Inc. | 3,100,086 | 16.4% | EDGAR |
| SC 13D/A | 2016-08-17 | Broadfin Capital, LLC | Recro Pharma, Inc. | 2,450,086 | 20.7% | EDGAR |
| SC 13G | 2016-07-21 | STONEPINE CAPITAL, L.P. | Recro Pharma, Inc. | 524,002 | 5.5% | EDGAR |